Daily Brief India: Quess Corp Ltd, NIFTY Index, Anthem Biosciences and more

In today’s briefing:

Quess Corp Demerger: Value Unlocking & Strategic Shift to Drive Growth

Quess Corp Ltd (QUESS IN) is strategically demerging into 3 distinct segments, enabling focused strategies and boosting growth potential for each, paving the way for greater success and innovation.
Previously, the high-margin Global Technology Solutions segment contributed 12% of revenue, but its potential was overlooked within the larger company. Now, with demerging, it gains specialized focus and proper valuation.
The demerger gives investors the flexibility to choose between cash-generating, high-margin, or moderate-margin businesses, with the added option of a platform for job hunting, all backed by focused, specialized management.

The NIFTY Index (NIFTY INDEX) has reached 22939 on Wednesday, our model indicates that if the index reaches the 23320 target, there would be a 75% probability of pullback.
From the perspective of our time model, the index could continue to rise for at least 1 more week.
We conclude that it’s possible that the index keeps rallying 1 more week towards 23320, then a pullback could start – for now the index seems stuck in its downtrend.

Anthem Biosciences (1234D IN) is looking to raise up to US$400m in its upcoming India IPO.
Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.
In this note, we talk about the not-so-positive aspects of the deal.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network